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 This case study focuses on the effectiveness of the recent regulations imposed upon 
Massachusetts’s prescription monitoring program. Abuse and/or misuse of prescription opioids is 
becoming increasingly problematic within the United States and as a result many policy makers 
are looking for ways to combat the problem. In Massachusetts, the OxyContin and Heroin 
Commission was established to investigate the impact of both OxyContin and heroin on the state. 
The Commission delivered recommendations that eventually led the state legislature to make 
changes to Massachusetts’s prescription monitoring program. This study targeted five major 
stakeholder groups and asked a series of questions through interviews and surveys. The research 
question was as follows: do major stakeholders see the recent regulations imposed upon the 
states prescription monitoring program as being effective in helping to combat abuse and misuse 
of prescription opioids in Massachusetts? Findings produced two main themes: 1) stakeholders 
believe prescription monitoring programs are successful in combating prescription drug abuse 
and/or misuse and, 2) there is an overwhelmingly negative attitude towards Massachusetts 
program design. Recommendations include determining how widespread the feelings of 
negativity and general lack of knowledge are felt across the Commonwealth, to educate users on 
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A case study of the regulation imposed upon 
Massachusetts’s prescription monitoring program 
Introduction 
Historically, drug addiction, abuse and misuse has been a sensitive subject that many 
people tend to shy away from acknowledging or even discussing in social settings. In reality, a 
large number of individuals, as well as their families, struggle with the horrors of drug addiction, 
abuse and/or misuse on a daily basis. According to the United States Food and Drug 
Administration (FDA) more than 16,000 lives are lost each year due to opioid-related overdoses 
(2014). In many cases addicts, abusers, misusers and their families struggle in silence because 
they fear how society will judge them. However, in recent years the misuse and abuse of 
prescription opioid drugs has become increasingly more prevalent and problematic within the 
United States (National Institute on Drug Abuse, 2011). The number of unintentional opioid 
related overdoses increased from approximately three thousand in 1999 to twelve thousand in 
2008 (National Institute on Drug Abuse, 2011). As a result, the issue of prescription drug abuse 
and/or misuse is now affecting a significantly wider range of people than ever before. There are a 
number of reasons why the misuse and abuse of prescription opioid drugs has become 
problematic, including but not limited to the following: 1) these types of drugs are now more 
readily available than ever before, 2) many people do not realize how addictive the drugs can be, 
3) there is a common misconception that they are “safer” than other drugs because a doctor 
prescribes them, and 4) they give the same recreational high as heroin yet come with less of a 
social stigma (National Institute on Drug Abuse, 2011).  
OxyContin is one prescription opioid that has been receiving significant attention in 
recent years for being highly addictive and frequently abused and/or misused. Misuse is defined 
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as taking a prescription medication for a purpose or in a manner other than it was prescribed, or 
taking a prescription medication that was not prescribed to that particular person. In contrast, 
“abuse” of a prescription drug is when a person takes a prescription drug to achieve a euphoric 
high or for recreational purposes alone (Federal Drug Administration, 2010). OxyContin is a 
prescription pain pill that offers an extended release of oxycodone hydrochloride to help 
individuals with moderate to severe pain that requires relief for several days or more (Cicero, 
Inciardi and Munoz, 2005). Significant opioid misuse and abuse can be linked to the market 
introduction of OxyContin in 1996, mainly because of its addictive tendencies and availability. 
In fact, opioid addiction rates in Massachusetts increased by 950% between 1996 and 2006 
(Massachusetts OxyContin and Heroin Commission, 2009). 
As a result of prescription opioid misuse and abuse becoming increasingly problematic, 
many states have imposed regulations upon the prescription drug industry at large (Garcia, 
2013). The majority of these regulations are intended to combat the misuse and abuse of such 
drugs by placing more accountability and obligation upon those who are not only prescribing the 
drugs, but also those who dispense them. In Massachusetts, the OxyContin and Heroin 
Commission was created under Chapter 302 Section 56 of the Acts of 2008 by the State 
Legislature to investigate the impact of both OxyContin and heroin on the state and in turn make 
policy recommendations to help combat the issue. 
The recommendations made by the OxyContin and Heroin Commission aim to ensure 
that doctors and pharmacists are held to a higher standard, and require them to better manage and 
monitor the prescriptions they prescribe or dispense. The regulations that have been imposed are 
relatively recent and the long term effects have yet to be determined. Therefore, this study will 
focus on the short term effectiveness of the regulations pertaining to the states Prescription 
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Monitoring Program. Specifically, this case study will determine how the recent regulations are 
affecting several stakeholders and determine whether those stakeholders see the regulations as 
being effective and/or helpful in combating the misuse and abuse of prescription opioid drugs in 
Massachusetts.  
The research question is as follows: do major stakeholders see the recent regulations 
imposed upon the states prescription monitoring program as being effective in helping to combat 
abuse and misuse of prescription opioids in Massachusetts? In addition, the larger question of 
how major stakeholders have been impacted as a result of the recent regulations will also be 
addressed. 
This case study will provide information on how the industry in Massachusetts has 
changed as a result of the regulations. In addition, the case study will contribute to overall 
research on the topic by potentially uncovering adverse effects or unintended consequences of 
the regulations that should be considered when developing further policy recommendations. At 
this time there is a lack of research on how these regulations function in terms of success and/or 
failure and how they affect different stakeholders. This case study will examine best practice 
standards for prescription monitoring programs and help to determine if the recent regulations 
surrounding Massachusetts’ state program are functioning as intended and in line with best 
practice standards.    
History/Context 
OxyContin is readily available for several reasons. In many cases the drug is legally 
distributed to pharmacies and then makes its way to the black market through diversion, fraud, 
false prescriptions, and doctor shopping (Massachusetts OxyContin and Heroin Commission, 
2009). Diversion occurs when a prescription drug is dispensed or distributed in a manner other 
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than its intended purpose. Doctor shopping is when abusers target doctors that are known to be 
careless or sympathetic when prescribing or when a person visits multiple doctors and 
pharmacies in order to obtain multiples of the same prescription. In addition, some patients will 
sell their prescriptions for profit. The profitability is significant and serves as a motivator for 
diversion because OxyContin can be sold for up to $100 per tablet on the black market. Abusers 
of OxyContin are known to crush the pill in order to destroy the time-release feature, and either 
snort, inject or chew the tablet in order to achieve a euphoric high (Massachusetts OxyContin 
and Heroin Commission, 2009). The high that is associated with destroying the time-release 
feature is comparable to the high that is associated with heroin, making these two drugs virtually 
interchangeable. Studies have shown that many OxyContin abusers will eventually turn to heroin 
because it is cheaper and even more readily available than OxyContin (Massachusetts OxyContin 
and Heroin Commission, 2009).  
Accounts of prescription drug abuse leading to heroin use are becoming more and more 
prevalent in today’s news stories. According to a Boston Globe article dated February 18, 2014, 
the City of Taunton witnessed 64 incidents related to heroin in a month and a half with 5 of those 
incidents resulting in death (Sampson and Anderson, 2014). The article also states that’s 
advocates at the community meeting stressed that majority of users do not start off with heroin, 
but rather transition to the drug after first being prescribed opiates. In addition, a report on 
February 9, 2014 in the Vermont Valley News, law enforcement officials stated that they 
encounter heroin on a daily basis and most of it is reportedly coming from Massachusetts 
(Fleisher, 2014). As a result of such instances and the growing number of opiate related 
overdoses and deaths, Governor Deval Patrick recently declared a public health emergency in the 
state of Massachusetts (MacQuarrie, 2014).  
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Research shows that prescription drug abuse has increasingly become an issue for a wide 
range of people varying in age and background (Grau, et. al, 2007). Due to the fact that this issue 
is reaching a multitude of different people, prescription painkiller abuser is now considered to 
have reached epidemic proportions (Garcia, 2013). As a result, prescription drug abuse is no 
longer perceived as an individual struggle but rather a social issue that warrants public 
consideration. The Massachusetts OxyContin and Heroin Commission (2009) stated that opiate 
addiction within the Commonwealth has reached epidemic proportions larger than was seen with 
the flu pandemic, which constitutes this as a serious public health issue that warrants careful 
consideration and attention.  
The Massachusetts OxyContin and Heroin Commission was established in the 2007-2008 
legislative session to investigate the issues surrounding OxyContin, heroin and other opioid 
abuse and misuse within the Commonwealth. The Commission was comprised of legislative and 
gubernatorial appointments who examined various policies surrounding substance abuse, the 
total direct and indirect cost of said policies, how opioid drugs are making their way to the streets 
and how families across the Commonwealth are being impacted by the issue. In turn they were 
expected to make policy recommendations that would help combat the growing opioid epidemic. 
The Commission delivered recommendations relating to the following policy areas: 1) 
prevention and education, 2) distribution, dispensing and handling, 3) prescribing and 
monitoring, and 4) expansion of access to treatment services (Massachusetts OxyContin and 
Heroin Commission, 2009).   
The Massachusetts OxyContin and Heroin Commission was established during a time 
when the Commonwealth was facing a serious problem. Not only had OxyContin abuse and/or 
misuse reached epidemic proportions but the state budget was also greatly impacted trying to 
A CASE STUDY OF THE REGULATIONS IMPOSED UPON MA 
11 
 
combat the issue. In 2005, the total cost of substance abuse and addiction to the Commonwealth 
amounted to 21.8% of the state’s total budget. In addition, the state paid nearly $200 million in 
emergency room costs related to opioid related overdoses (Massachusetts OxyContin and Heroin 
Commission, 2009). Furthermore, in 2002, Boston had the highest rate of OxyContin related 
emergency room visits in the country (Massachusetts OxyContin and Heroin Commission, 
2009).  
Despite the fact that over $4.5 billion was spent on substance abuse and addiction, 
Massachusetts was ranked in the lower 50% of states in terms of total money spent on 
prevention, treatment and research (Massachusetts OxyContin and Heroin Commission, 2009). 
Only 2% of the $4.5 billion, or $66 million, was spent on prevention, treatment and research 
(Massachusetts OxyContin and Heroin Commission, 2009).  The report presented to the 
legislative body of the Massachusetts State House in November of 2009 included 20 policy 
recommendations to update existing laws and create new laws pertaining to prescribing and 
dispensing substances that are controlled by the federal government and subject to regulation by 
the Drug Enforcement Agency (Massachusetts OxyContin and Heroin Commission, 2009). 
The Commission revealed that the state’s prescription monitoring program was failing to 
be an effective resource in combating the opiate epidemic. As a result, the commission made 
several recommendations to improve the state’s prescription monitoring programs in hopes of it 
being used as an effective preventative tool. The Commission stated that although completely 
stopping misuse and/or abuse of prescription drugs is highly unlikely, reducing reckless or 
fraudulent distribution of the drugs is a realistic goal. Therefore, they concluded that one of the 
most efficient ways to stop fraud and limit the availability of opioid prescriptions is to have an 
active and useful prescription monitoring program.   
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As a result of the recommendations made by the Commission, the Massachusetts State 
Legislature eventually adopted legislation to reform state regulations. An Act Relative to 
Prescription Drug Diversion, Abuse and Addiction was adopted in August of 2012 and became 
Chapter 244 of the Acts of 2012. The legislation most notably made changes to Massachusetts’ 
prescription monitoring program. Prescription monitoring programs maintain statewide 
databases that contain information regarding prescriptions that have been dispensed containing 
controlled substances. According to the Massachusetts Department of Public Health (2014) the 
goal of prescription monitoring programs are to promote safe prescribing and dispensing and to 
assist in addressing prescription drug misuse and abuse.  
Under the new legislation, the Department of Public Health is charged with ensuring that 
all prescribers who are licensed to prescribe a controlled substance are automatically enrolled in 
the state’s prescription monitoring program upon license renewal. In addition, it is now 
mandatory for prescribers to check the database for all new patients, which was not required in 
years past. In addition, the Act grants expanded database access to pharmacists within the 
Commonwealth. Practitioners and pharmacists in Massachusetts are required to fill out an 
enrollment form in order to be granted access, which can be viewed in Appendices A and B.   
The Commission concluded that their recommendations surrounding prescription 
monitoring were the most promising of all the recommendations. They stated that resuscitating 
and improving the states program would help combat the opioid epidemic as well as save money 
for the Commonwealth. The recommendations surrounding the states prescription monitoring 
program were intended to make the program more accessible to non-governmental stakeholders 
such as pharmacists and prescribers and ensure that real time data is available and can flow in a 
non-restrictive and streamlined fashion.  





 Because prescription drug abuse and misuse has only been considered a social issue in 
the recent past, there has not been extensive research on the long term effects of regulating 
prescribing and dispensing of pharmaceuticals. However, significant research has focused on the 
regulations and how they affect different stakeholders in the short term. Policy makers have been 
charged with creating regulations that limit prescription drug diversion but at the same time do 
not interfere with adequate treatment of pain. In many cases, satisfying both objectives can be a 
challenge. According to Fishman et al. (2004), state and national organizations are considering 
under treatment of pain as a serious public health problem, underscoring the need for finding a 
balance between properly regulating prescribing and dispensing prescription drugs and proper 
treatment of pain. Many scholars believe that prescription monitoring programs promote more 
informed prescribing without deterring practitioners from prescribing controlled substances 
when needed (Perrone and Nelson, 2012). The National Alliance for Model State Drug Laws 
specifies that prescription monitoring programs are intended to do just that; support legitimate 
medical use of controlled substances while limiting diversion, misuse and abuse (Gugelmann and 
Perrone, 2011).   
Many researchers support the use of prescription monitoring programs. Prescription 
monitoring programs were first established in 1989, with only 9 states participating in some 
capacity. By 2013, 49 out of 50 states had adopted some type of prescription monitoring program 
with the intention of better identifying inappropriate prescribers, their dispensing patterns, and to 
detect drug seekers and monitor behaviors (Garcia, 2013). Paulozzi et al. (2011) state that with 
proper program design, prescription monitoring programs have proven to be successful in 
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reducing misuse and abuse of prescription drugs. Garcia (2013) supports this claim and stresses 
the need for proper program design in order to reduce doctor shopping along with change 
prescribing behaviors. A survey of substantial literature regarding prescription monitoring 
programs produced two major themes relating to how an ideal program is run: 1) real time data 
and 2) access.    
Real Time Data   
 In the pre-internet era, programs that required data input and sharing of data, such 
as prescription monitoring programs, were not very effective. According to Fishman et al. 
(2004), non-computerized monitoring programs actually had a negative impact on areas of 
legitimate medical care because pharmacists were prescribing based on outdated information. 
However, due to the development of the Internet, prescription monitoring programs are no longer 
facing limiting factors such as reporting with paper documentation, and the voluntary nature of 
reporting (Perrone and Nelson, 2012). Presently collecting and sharing real time data is not only 
a possibility, but it is easier than ever before with the help of electronic data transmission 
systems (Fishman et al., 2004). According to the Massachusetts Department of Public Health 
(2014) Massachusetts’s prescription monitoring program is in fact a computer-based, Electronic 
Data Transfer system (EDT).     
Clark et al. (2012) state that real time data that is constantly available is critical for the 
success of a prescription monitoring program, particularly in cases where dispensing occurs at 24 
hour facilities. Therefore, it is critical to ensure that it is not burdensome or time consuming for 
pharmacists to upload information to the prescription monitoring program and encourage them to 
do so in a timely manner (Perrone and Nelson, 2012). Clark et al (2012) state that ideally, 
prescription monitoring programs should collect data within minutes of dispensing. According to 
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the Massachusetts Department of Public Health (2014) pharmacists are required to input data 
into the state’s prescription monitoring program on a weekly basis but they are not mandated to 
consult the database before dispensing a prescription. In addition, the regulations encourage 
pharmacists to use professional judgment in deciding when to consult the database before 
dispensing (Ryle, 2013).  
Gugelmann and Perrone (2011), discuss a study conducted in 2010 that supports the need 
for information that is updated in real time. The study looked at 179 clinical records that were 
reviewed by practitioners in Ohio’s prescription monitoring program database.  Having real time 
data available resulted in the practitioners changing their prescription practices in 41% of their 
interactions with patients.  
 Many believe that the quality of a patient’s care can be significantly improved if those 
who are responsible for the patient have access to up-to-date, live information. According to 
Brushwood (2003), effective prescription monitoring programs provide feedback regarding a 
patient’s history in a timely manner to physicians and pharmacists who are responsible for that 
patient. Perrone and Nelson (2012) argue that in order for a prescription monitoring program to 
be most valuable in clinical practice, it must be current. According to Clark et al. (2012), varying 
intervals of data collection compromise the utility of the data and significantly limits the success 
of the prescription drug monitoring program. In Massachusetts, practitioners are required to 
consult the database only when treating a new patient (Department of Public Health, 2014). This 
could potentially be problematic because physicians may have current patients that are abusers 
and or/misusers which would go undetected. Whereas, states such as Rhode Island and 
Connecticut require practitioners to consult the database every time they prescribe a controlled 
substance, in an attempt to avoid such misdetections (Rhode Island Department of Health, 2014; 
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Connecticut Department of Consumer Protection, 2014).   
 Furthermore, research shows that effective prescription monitoring programs must be 
comprehensive and accurate in data reporting. Brushwood (2003) describes a comprehensive 
program as one that requires the reporting and aggregation of data of all controlled substances 
that are dispensed versus only schedule II drugs. The United States Drug Enforcement 
Administration classifies drugs, substances, and certain chemicals used to make drugs into five 
categories or schedules ranging from I-V based on the drug’s acceptable medical use and the 
drug’s abuse or dependency potential. Schedule I drugs have the highest potential for abuse 
and/or dependence whereas Schedule V drugs have the least potential for abuse and/or 
dependence (United States Drug Enforcement Administration, 2014). Brushwood (2003) goes on 
to state that not having a comprehensive program could result in not catching shifts in drug 
seeking behaviors. In Massachusetts, community pharmacies, hospital outpatient and clinical 
pharmacies as well as out of state mail order pharmacies that service patients in Massachusetts 
are required to report to the states prescription monitoring program (Massachusetts Department 
of Public Health, 2014). In addition, Massachusetts’s prescription monitoring program reports on 
schedule II-V drugs and includes extensive information such as fill date, quantity, prescriber, 
dispensing pharmacy and insurance information (Ryle, 2013).    
Research also shows that it is important to be comprehensive regarding the different 
types of pharmacies that are available (Brushwood, 2003). For example, mail order, internet 
pharmacies, hospital and retail pharmacies should all be required to report to the prescription 
monitoring program within their respective patient’s state. Perrone and Nelson (2012) claim that 
in order to truly be effective all monitoring programs should have comprehensive information on 
the prescriber, the patient, the pharmacy, generic name of the drug, the dosage prescribed, 
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number of units dispensed, and the dates of both prescribing and dispensing. In addition, 
Brushwood (2003) argues that maintaining accuracy when inputting and using patient data is 
critical for a prescription monitoring program to be effective. If the data that is being reviewed is 
not accurate or even outdated then the purpose of the program is lost.  
Access  
  The second major component to running a successful prescription monitoring program is 
allowing user-friendly and standardized access for a variety of stakeholders. Interstate access is a 
major hindrance for the effectiveness of prescription monitoring programs and failure to share 
data amongst states can lower the effectiveness of prescription monitoring programs. Since each 
state is charged with implementing and maintaining their own program, prescription monitoring 
programs vary greatly from state to state (Garcia, 2013). Such differences include the types of 
drugs that are reported, when prescribers are required to consult the database, how often 
dispensers must report data to the system, what stakeholders have access to the data, and whether 
the data can be shared with other states or not (Garcia, 2013). The chart below (figure 1) shows 
how the Massachusetts’s prescription monitoring program compares to both Rhode Island and 
Connecticut’s prescription monitoring programs in terms of who has access to the database, how 
often it is updated, when prescribers are required to consult the database, what drugs are 
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 (Figure 1 – MA prescription monitoring program compared to RI and CT) 
 
According to Gugelmann and Perrone (2011) with no set standard for all prescription 
monitoring programs the result is inaccuracy and error within the systems.  Perrone and Nelson 
(2012) go on to state that variations in data collection from state to state limits the effectiveness 
of the monitoring systems. Gugelmann and Perrone (2011) state that despite efforts from the 
United States Bureau of Justice to use federal funds to support interstate access, the success of 
prescription monitoring programs continues to be limited by variability in access across the 
states. Some states allow for prescribers, pharmacists and special law enforcement whereas other 
states only allow special law enforcement authorities to access the information in the database 
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(Gugelmann and Perrone, 2011). Brushwood (2003) claims that without a unified system it is 
impossible for prescription monitoring programs to function as intended. In addition, Clark et al. 
(2012) state that an ideal prescription drug monitoring program would have standardized, 
continuous access that meets the needs of the user.   
 Interstate collaboration and the creation of a national standard regarding information-
sharing is essential. For example, Perrone and Nelson (2012) state that in urban areas that abut 
state borders, interstate access is crucial in reducing diversion. Reisman et al. (2009) support this 
claim by stating that interstate access allows for easier identification of doctor shoppers who 
cross state lines to fraudulently obtain controlled substances in two different states. Paulozzi et 
al. (2011), state that some prescription monitoring programs grant pharmacists the ability to 
capture a unique serial number that is associated with each prescription. The serial number can 
then be tracked to help identify duplicate prescriptions or stolen forms submitted at other 
pharmacies. If this type of access were granted to pharmacists nationwide, it would be much 
more difficult for drug seekers to doctor shop across state lines.  
 In addition to granting standardized, user-friendly access to pertinent stakeholders 
nationwide it is important that the application process is not cumbersome. According to 
Gugelmann and Perrone (2011) proper access to a patient’s full prescription history allows for 
more informed prescribing on the part of the physician, and therefore less diversion and opioid 
abuse. Informed prescribing not only allows for less diversion and abuse, but it also promotes 
healthy and appropriate treatment of pain. Perrone and Nelson (2012) go on to state that in 
addition to granting access, states should focus their attention on making the log-in and 
application process simple and user-friendly. Having simple and user-friendly processes to gain 
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access to the database would allow for a less cumbersome and frustrating experience, and 
encourage more consistent usage.  
Research Methodology 
Overview 
 Drug abuse and misuse is a complex social issue that requires sensitivity within the 
research method in conjunction with in depth analysis. Overall, the goal of this study was to 
determine how different stakeholder groups feel regarding the effectiveness of the recent 
regulations imposed upon the state’s prescription monitoring program. In particular this study 
examined how stakeholders feel regarding the overall success of prescription monitoring 
programs in general as well as gauge their perspectives on the effectiveness of the regulations in 
terms of helping to combat drug abuse and misuse within the Commonwealth.  
For this case study two methods of qualitative data collection were utilized: 1) in depth 
interviews and 2) a survey. In addition the study targeted five key stakeholder groups including 
the following: 1) legislators who served on the OxyContin and Heroin Commission in 
Massachusetts, 2) both hospital and retail pharmacists who have experience with prescription 
monitoring programs, 3) doctors and organizational representatives who have experience and/or 
knowledge of opioid prescribing, 4) a sampling of recovering opioid addicts and, 5) substance 
abuse counselors. Perspectives from all five of these stakeholder groups helped to determine 
reoccurring themes in addition to any gaps in how different stakeholders view the effectiveness 
of the recent regulations. This study also provided insight as to how the stakeholders feel 
regarding the success of prescription monitoring programs in general.   
Research Method 
 The research method was based on qualitative data that was generated through a single 
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case study approach consisting of five subjects of analysis within the state of Massachusetts. 
This study was based on a convenience sample and all subjects were contacted by email or via 
the phone. Participants from all five stakeholder groups were asked to contribute on a voluntary 
basis with no financial incentive. Data collection was conducted through a series of face-to-face 
or phone interviews and surveys. The subjects of the interviews and participants of the surveys 
were required to give informed consent prior to data collection. The letter of informed consent 
for all participants can be viewed in Appendix H. The identity of all research participants 
remained confidential throughout the entire process, and data will be destroyed when the study is 
complete. All interviews were recorded, and transcribed. The data was analyzed through a 
comparative process to determine any reoccurring themes or inconsistencies between the 
stakeholders.     
Interviews 
 In depth interviews were conducted face to face or over the phone with subjects from 
four of the five stakeholder groups. One of the targeted groups consisted of a sample size of two 
members from the Massachusetts State Legislature who have experience with the subject matter. 
This particular study targeted legislators that served on the Massachusetts OxyContin and Heroin 
Commission. The OxyContin and Heroin Commission was established in the 2007-2008 
Legislative Session to study the growing opioid abuse epidemic in Massachusetts. As stated 
earlier, the Commission released a report with findings on the subject and recommendations on 
how the state should proceed in handling the growing epidemic.  
The legislators were asked a series of questions pertaining to their contributions to the 
Commission, their knowledge of opioid abuse and misuse prior to being on the Commission, the 
current regulations surrounding the states prescription monitoring program, the recommendations 
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that were made by the Commission and how they feel regarding the effectiveness of those 
recommendations at this time. The interview questions for legislators are outlined in Appendix 
C. Face to face or phone interviews were selected for this group because legislators may be able 
to offer additional information regarding their experience or knowledge of the subject outside of 
the interview questions that may add to the research. Subjects for this group will be recruited and 
contacted through their official capacity at the Massachusetts State House, or if they have since 
left the legislature through their current profession.     
 The second stakeholder group that was targeted is pharmacists. In order to gain a broad 
perspective both hospital and retail pharmacists were targeted. This study focused on a sample 
size of nine pharmacists that either had experience with prescription monitoring programs in 
Massachusetts, prescribing opioids themselves or were knowledgeable in prescribing opioids in 
general. The Prescription Monitoring Program used in Massachusetts is online and is a secure 
website that supports safe prescribing and dispensing. Massachusetts’s regulations now require 
pharmacies to use the Online Prescription Monitoring Program, which exposes the majority of 
pharmacists in Massachusetts to the recent regulations.  
The pharmacists were asked a series of questions regarding their experience using the 
prescription drug monitoring program, their views on the effectiveness of the recent regulations 
surrounding prescription monitoring programs, how they feel regarding the effectiveness of the 
regulations in terms of helping to combat drug misuse and abuse, and their views on over and 
under prescribing by doctors. The interview questions for pharmacists are outlined in Appendix 
D. Face to face and phone interviews were conducted with this group because as professionals 
they may be able to offer additional pertinent information relating to the subject matter that is not 
covered in the interview questions. Subjects for this group were recruited and contacted through 
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their official capacity at either local retail pharmacies or through local pharmaceutical hospital 
contacts.   
 The third stakeholder group that was targeted is doctors. In order to gain a broad 
perspective both physicians and organizational representatives were targeted. The sample of four 
doctors with experience prescribing pain medication brought a unique perspective due to the fact 
that the recent regulations have changed the way in which their industry operates. This study 
targeted physicians that treat chronic pain because they had experience prescribing opioids 
themselves. The doctors were asked a series of questions regarding how the regulations have 
affected their ability to do their job, their thoughts surrounding misuse and abuse of opioids in 
general, their views on under and over prescribing in general, and how they feel regarding the 
effectiveness of the regulations surrounding prescription monitoring programs in terms of 
helping to combat drug misuse and abuse. The interview questions for doctors are outlined in 
Appendix E. This stakeholder group was interviewed face to face or over the phone because the 
doctors may be able to offer additional information or insight not covered within the questions 
based on their personal and professional experience. Subjects for this group were recruited and 
contacted through the states medical association.  
 The fourth stakeholder group that was interviewed face to face or over the phone for data 
collection is substance abuse counselors. In addition to surveying recovering opioid addicts, 
substance abuse counselors were targeted in order to gain a broader perspective. The sample size 
of this group consisted of two people. The substance abuse counselors were asked a series of 
questions regarding how their patients are most commonly introduced to opioid drug, how they 
most commonly become addicted and how they most commonly obtain the drugs on a regular 
basis. This data provided insight on how and why prescription drugs are most frequently 
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misused, abused and/or making their way to street in Massachusetts. Lastly, they were asked a 
series of questions regarding the recent regulations surrounding prescription monitoring 
programs, and their views on the effectiveness of such regulations. The interview questions for 
recovering substance abuse counselors are outlined in Appendix F. For this stakeholder group 
face to face or over the phone interviews were conducted because they may be able to offer 
additional information or insight not covered within the questions based on their personal and 
professional experience. Subjects for this group will be recruited and contacted through their 
official capacity. 
Surveys  
 The fifth stakeholder group that will be targeted for data collection is recovering opioid 
addicts. The sample size will be eight individuals and the identity of participants who fill out the 
surveys will be kept anonymous for confidentiality purposes. This stakeholder group will 
provide an important perspective because these are the people who have experience with 
addiction, and know how the drugs are commonly being misused and abused from personal 
experience. The survey will ask a series of questions regarding how the participant was 
introduced to the drug, how they became addicted and how they obtained the drugs on a regular 
basis. This data will provide insight on how and why prescription drugs are most frequently 
misused, abused and/or making their way to street in Massachusetts. Lastly, they will be asked a 
series of questions regarding recent regulations surrounding prescription monitoring programs, 
and their views on the effectiveness of such regulations. The survey questions for recovering 
addicts are outlined in Appendix G. For this stakeholder group a survey is being conducted 
because of the sensitive nature of the questions being asked. The participants may not feel 
comfortable sharing such personal details in a face to face setting. Subjects for this group will be 
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recruited and contacted through local substance abuse counselors.     
Results/Findings 
Overview   
 Significant data was collected from a variety of sources within all five stakeholder 
groups: 1) legislators, 2) both hospital and retail pharmacists who have experience with 
prescription monitoring programs, 3) doctors and organizational representatives who have 
experience and/or knowledge of opioid prescribing, 4) substance abuse counselors and 5) a 
sampling of recovering opioid addicts. Face to face or phone interviews as well as a series of 
surveys yielded data from two legislators, nine pharmacists, three doctors, one medical 
organizational representative, two substance abuse counselors and eight recovering addicts. Two 
main themes were established throughout the interviews and surveys which are as follows: 1) 
stakeholders in Massachusetts believe prescription monitoring programs are successful in 
combating prescription drug abuse and/or misuse and, 2) stakeholders in Massachusetts have an 
overwhelmingly negative attitude towards Massachusetts program design.  
Prescription Monitoring Programs are Successful 
  A large number of the subjects believed that prescription monitoring programs are (or 
have the potential to be) successful in combating prescription drug abuse and/or misuse. Both 
legislators stated that they believe prescription monitoring programs are a successful way to 
combat prescription drug abuse and/or misuse. One in particular claimed that “Prescription 
monitoring programs are one of the ways we can help reduce prescription drug abuse. We all 
know that these drugs need to be prescribed by a licensed physician. Drug monitoring programs 
allows us to track who and more importantly how many prescriptions are being prescribed.” The 
other subject went on to state that “prescription monitoring programs can help us find legitimate 
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versus illegitimate prescribers.” That same subject then stressed the need for proper program 
design when developing a prescription monitoring program, “I believe prescription monitoring 
programs have the potential to be successful, if implemented properly.”  
 All of the pharmacists responded positively when asked if they believed prescription 
monitoring programs are successful in combating prescription drug abuse and/or misuse. One 
subject responded with “Yes!” while another stated “Yes, I believe prescription monitoring 
programs help reduce abuse and misuse of drugs.” Another subject went on to state “They are 
definitely helpful. I have seen it! I’ve had doctors call and tell us to cancel refills on a controlled 
substance since the patient was identified on PMP.” Lastly, one of the pharmacist subjects stated 
that “prescription monitoring programs are definitely helpful, but still relatively new. I think as 
more time passes and it becomes more used by RPh (Registered Pharmacist)/ MD (Doctor of 
Medicine) it will help to actually curb the misuse of prescription drugs.”   
 Half of the doctors that were interviewed felt as though prescription monitoring programs 
are successful in combating prescription drug abuse and/or misuse. One subject stated that “I 
think they can and potentially will be successful, baring implementation.” While another one of 
the doctors stated “Yes, they are successful. However, the way in which prescription monitoring 
programs are run could be improved. A centralized database that crossed state lines would be 
better.” 
 The substance abuse counselors that were interviewed vastly believed that prescription 
monitoring programs are successful in combating prescription drug abuse and/or misuse. One 
subject stated “Absolutely, I have already seen it in action. Patients in treatment who were 
receiving prescriptions that we weren’t aware of, we are now aware of. More importantly, it 
opens a discussion between patients and their physicians.” The other subject said “I love the 
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PMP. I see a lot of patients from New Hampshire that do not have one and there is a clear 
difference – it is scary. We should consider adding Suboxone and methadone to the database that 
would greatly benefit substance abuse counselors.”  
The recovering addicts that were surveyed were not familiar with prescription monitoring 
programs.    
Negative Attitude / Lack of Knowledge 
 Throughout the interviews and surveys an overwhelmingly negative attitude and general 
lack of knowledge surrounding Massachusetts’s prescription monitoring program emerged from 
many of the stakeholders, which was surprising given that most of the stakeholders felt as though 
prescription monitoring programs are successful. One of the legislators stated that “The 
recommendations of the commission for the states prescription monitoring program were 
positive, but Massachusetts is nowhere near meeting those goals.” That same subject went on to 
state the Department of Public Health needs to find more innovative ways to improve 
Massachusetts’ prescription monitoring program, “If the Department of Revenue can track 
parking tickets in real time, why can’t the Department of Public Health find a way to track this 
data real time.” The other legislator stated “More needs to be done in strengthening the states’ 
program. More collaboration needs to exist among federal and state officials.”  
 The pharmacists also portrayed a negative attitude and general lack of understanding. 
One subject stated “Massachusetts program could be effective if we put serious resources 
towards making it better.” Whereas another subject stated “I believe it has helped to some extent, 
but much more work needs to be done.” Another subject went on to say “I can check the 
prescription monitoring program, but what do you want me to do with that info? Electronic 
system is better than the old way; however, I have no idea who is even tracking the information.” 
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In addition, one subject stated “the database is not checked very often, there is a lag in real time 
information. Sometimes the information is not available when you need it, and then you find out 
later on that someone was doctor shopping when both pharmacies have a chance to upload the 
information.”            
 The doctors that were interviewed were extremely negative towards Massachusetts 
program design as a result of the regulations. One subject stated “The regulations were poorly 
drafted and would waste a lot of physicians time in looking up all new patients, regardless of any 
relationship to opioids much less a risk of abuse.” Another subject stated “Research should be 
done to pinpoint the connection between opioid abuse and prescribing. Research from the top 
down and interventions in identified areas of abuse will be more effective than mandating all 
practitioners to follow the dictates of the DPH.” Another subject stated “No, I don’t think the 
regulations will help in reducing abuse. Until doctors have more latitude to provide care to 
patients, have enough time to spend with them and are able to prescribe alternatives to narcotics 
it will be hard to do this justice.” In addition, one subject said “This is a multifactorial problem 
and like most things regulations look for easy unidirectional answers – those generally make 
things harder for the conscientious and don’t slow down the ones of concern. I wish they would 
talk to primary care doctors in practice and find out what the issues are and address those!”  
 One of the substance abuse counselors stated that “Massachusetts PMP can be 
cumbersome; having a delegate would be helpful.” In addition, one of the subjects was not 
familiar with the regulations at all “I am not familiar with the regulations, but all healthcare 
workers should know what other meds are being prescribed by other providers, and be vigilant 
about contradictions.”  
Other 
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 There were various findings throughout the case study that were not shared broadly 
across the group yet they were still noteworthy. One of the legislators stated “If the 
Commonwealth placed more resources in educating and rehabilitating those with drug issues, I 
truly believe there will be a reduction in overall crime and more importantly, a reduction in 
overdoses.”  One of the pharmacists stated that “regulating the industry has potentially made it 
more dangerous for patients. Prescription opioids are a gateway to addiction and when patients 
are addicted and cannot access these medications (or don’t have the support to break their 
addiction) they turn to more dangerous street drugs like heroin.” However, one of the doctors 
stated “Prescriptions are issued for the primary purpose of treating patients appropriately; we 
must not lose sight of this in a rush to respond to the established addiction and overdose 
problems in our society. Licensing boards have the clinical expertise to balance patient needs 
with proper practitioner standards of care. The DPH does not have broad based expertise in this 
area.”  
 Both the substance abuse counselors and the recovering opioid addicts felt as though 
people will continue to find the drugs no matter what types of regulations are put into place. One 
of the substance abuse counselors stated “As long as drugs are good and kill pain, people will 
want them. There are so many levels of issues to cover that I don’t know that any amount of 
legislation can cover them all and actually be effective.” In addition, when asked whether they 
believed regulating the prescription drug industry has helped to combat drug abuse all of the 
recovering addicts said no. One subject in particular stated “I don’t think it has had any effect. 
Making them harder to get doesn’t mean they cannot be found.” Another subject stated “I think 
they ought to help the addict, not make him/her turn to crime to get the drugs.” The perspectives 
of the recovering addicts is important and will be discussed in the paragraphs below.  




 The findings of this case study yielded very positive results in terms of how the 
stakeholders view the effectiveness of prescription monitoring programs in general. Majority of 
the stakeholders displayed positive feelings regarding the usefulness of prescription monitoring 
programs in conjunction with stressing the need for proper program design. However, there was 
an overwhelmingly negative attitude towards Massachusetts program design and a general lack 
of knowledge surrounding the prescription monitoring program itself. Subjects raised concerns 
ranging from real time data issues, the need for federal and state collaboration, interstate access 
and cumbersome and time consuming processes.  
The findings of this study are interesting because with the help of recent regulations, the 
Massachusetts’s prescription monitoring program design meets most of the technical components 
of an ideal prescription monitoring program. The program uses an electronic data transmission 
system, it has real time data capabilities and it is comprehensive and accurate. However, 
Massachusetts does not share data across state lines and there are no nationwide standards for 
who has access to the database.      
 Many complaints were lodged regarding real time data. One legislator questioned why 
the Department of Public Health has not come up with a way to track this information live. 
However, the capability to access real time information is there. It is not an issue regarding the 
technical components but rather an issue of physical resources. In order to have the information 
readily available pharmacists would have to be updating the database simultaneously as they 
were dispensing the drugs. A disadvantage to placing a requirement such as this on the 
pharmacists is that it would be extremely time consuming and an unrealistic expectation. In 
addition, some may argue that this type of pressure and added responsibility could potentially 
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affect the quality of service provided by the pharmacists.  
 Many of the stakeholders also claimed that more federal and state collaboration is 
needed. Federal and state collaboration would allow for interstate sharing and push the federal 
government to set a national standard for who has access to the database. Standardized access 
would allow for more comprehensive interstate sharing and increase the amount of information 
available to those who have access to the database. One may conclude that interstate sharing 
would be particularly beneficial to those practicing close to the border of neighboring states. 
Interstate sharing in Massachusetts would close the gap in terms of what Massachusetts’s 
prescription monitoring program design is lacking.  
 Several of the stakeholders, including those who are expected to use the program on a 
regular basis, displayed a general lack of knowledge regarding the state’s prescription 
monitoring program and the recent regulations surrounding the program. Many of the 
stakeholders were simply unaware of how the program was designed and how it is intended to 
function. The recent regulations allow for the creation of delegates to act on behalf of registered 
participants, and the OxyContin and Heroin Commission did consult with primary care 
physicians across the Commonwealth when drafting recommendations. The fact that some of the 
stakeholders were unaware of the provisions surrounding delegates and did not realize that the 
commission consulted with primary care physicians prior to making recommendations shows a 
lack of communication between the stakeholders and the policy makers. In addition, the fact that 
some of the pharmacists were unclear as to what happens with the information once they report it 
is an area that needs improvement.  
 It is important to note that a few of the stakeholders provided insight that was not 
consistent amongst all stakeholders, but was still pertinent to the overall discussion. One of the 
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legislators very adamantly stated that the opioid epidemic is a multilateral issue which warrants a 
comprehensive approach in terms of combating the overall problem. This statement was 
corroborated by one of the doctors who claimed that regulating the industry could potentially 
make it more dangerous for addicts or push them to turn to street drugs such as heroin. In 
addition, one of the recovering opioid addicts stated that policy makers should be helping the 
addict instead of forcing him or her to crime.  All of these statements warrant the consideration 
of policy makers regarding how the state is investing in rehabilitation services and what kind of 
access is available to those who are in need. This case study suggests that in addition to 
maintaining a fully functional prescription monitoring program a deeper look at the overall 
services available to addicts is necessary in order to truly combat opioid abuse and/or misuse 
within the Commonwealth.  
Recommendations  
 Definitive statements regarding further policy recommendations cannot be made at the 
conclusion of this case study. However, the research does suggest that further study is warranted 
and a different approach in terms of program design is desired.  The first recommendation is to 
determine how widespread the negative attitude and general lack of knowledge regarding the 
states prescription monitoring program truly is. Policy makers should be charged with organizing 
a commission, much like the OxyContin and Heroin Commission, to investigate and determine 
the attitudes and knowledge of stakeholders across the Commonwealth. This Commission should 
hold forums across the Commonwealth in order to gain insight as to how widespread the 
negative feelings and lack of knowledge is felt amongst stakeholders in Massachusetts. Insight 
from a larger sample of stakeholders will help to determine if further study and recommendations 
are needed. 
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The second recommendation is for policy makers and the Department of Public Health to 
develop a campaign to educate users on the benefits of the program, how the program is intended 
to function and to encourage routine use. For example, doctors should be encouraged to consult 
the database every time they prescribe a controlled substance, not just for new patients. In 
addition, pharmacists should be encouraged to update the database in a timely manner in order to 
help curb doctor shopping and diversion. If policy makers and the Department of Public Health 
want to restore faith in the Massachusetts’s prescription monitoring program they must educate 
the primary users on the benefits of such behaviors. In addition, it would be helpful to outline 
how Massachusetts program compares to other programs nationwide to give stakeholders a better 
sense of how Massachusetts is performing on a larger scale.  
The third recommendation is for policy makers and the Department of Public Health to 
engage the state’s licensing board. It is imperative that the pharmacists and physicians 
understand how the licensing board fits within the overall process and are educated on their 
procedures. These particular stakeholders should feel confident that any pertinent information 
that is funneled into the database is making its way to the licensing board when necessary. 
According to this case study, many stakeholders do not feel confident that the information they 
are submitting is making its way to the correct authorities. If the primary users of the system do 
not have faith in the overall purpose of the program it is inevitable that they will not regularly 
use the program.   
Limitations 
 There were a few limitations encountered throughout this case study. The main limitation 
was a condensed amount of time for research, in addition to the scope of research evolving over 
time. There were only two months in between IRB approval and the date of completion. This 
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time frame limited the amount of data collection for such a complex and wide ranging issue. In 
addition, it was somewhat difficult to get professionals to agree to be interviewed because of the 
sensitive nature of the topic and the fact that opioid abuse is an emerging issue in the 
Commonwealth at this time. Many potential participants were hesitant to open up about the issue 
in fear of jeopardizing their career by providing information they were not authorized to provide. 
In addition, the Department of Public Health was unwilling to communicate or give any 
perspective on the issue stating that the regulations were still a work in progress and they were 
not at liberty to discuss them.    
Conclusion 
 After extensive research and literature review, this case study revealed that further study 
and action on behalf of the policy makers and Department of Public Health is needed at this time. 
The research question was proposed as follows: do major stakeholders see the recent regulations 
imposed upon the states prescription monitoring program as being effective in helping to combat 
abuse and misuse of prescription opioids in Massachusetts? According to this case study the 
answer is inconclusive at this time. However, despite the fact that definitive statements regarding 
the larger population of stakeholders cannot be made, the study does suggest that although 
stakeholders in Massachusetts believe prescription monitoring programs are successful in 
combating prescription abuse and/or misuse they have a predominantly negative outlook 
regarding the program design of Massachusetts program in particular with regards to the recent 
regulations imposed upon the program.  Although Massachusetts’s prescription monitoring 
program appears to meet the technical components of a successful prescription monitoring 
program many of the pertinent stakeholders lack general knowledge on how the program is 
intended to function, are frustrated with the usability of the program and do not have faith in the 
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overall outcome.  
Due to the fact that prescription monitoring programs are still relatively new, additional 
research and assessment of different programs across the country is necessary in order to truly 
define the ideal prescription monitoring program. However, Massachusetts can make more of an 
impact in terms of combating prescription opioid abuse and misuse by encouraging routine use 
and educating users in order to garner additional support of the program.  In addition to 
maintaining a useful prescription monitoring program policy makers and other governmental 
authorities must commit to supporting other initiatives surrounding substance abuse in order to 
achieve the overall goal of decelerating the opioid epidemic in Massachusetts. On March 27 of 
this year Governor Deval Patrick stated that he would commit $20 million in additional funds to 
increase drug treatment and recovery services (State House News Service, 2014). This is a step 
in the right direction, however, a more detailed and extensive plan is needed in the near future. 
The legislature must act, and they must act fast in order to truly have an impact in terms of 
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1) How long have you been a member of the Massachusetts state legislature?  
2) How did you become a member of the OxyContin and Heroin Commission? 
3) Prior to being on the Commission what were your thoughts on prescription opioid 
abuse being a problem in MA? Did that change throughout the process of being on 
the Commission? How so?    
4) Are you familiar with how prescription monitoring programs? If yes, can you 
elaborate on how they are intended to function as a result of the recommendations of 
the commission? 
5) Do you feel that prescription monitoring programs are successful in combating 
prescription drug abuse?  
6) Do you personally believe that over-prescribing and/or under-prescribing is an issue 
in MA? If yes to either, can you elaborate on how so? 
7) Is there anything you think the Commonwealth should be doing in order to combat 
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Appendix D  
 
1) How long have you been working within the pharmaceutical industry?  
2) Are you licensed to dispense drugs containing opioids? 
3) Are you familiar with the recent regulations imposed upon the states prescription drug 
monitoring program? If yes, can you elaborate on them?  
4) Can you explain how prescription monitoring programs work?  
5) In your professional opinion, do you believe prescription monitoring programs are 
successful in reducing abuse and misuse of prescription drugs? 
6) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in 
MA? If yes to either, can you elaborate on how so? 
7) In your opinion, do you believe that regulating the states prescription drug monitoring 
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Appendix E  
 
1) How long have you been working within the medical industry?  
2) Are you licensed to prescribe drugs containing opioids?  
3) How effective do you think opioids are in terms of treating pain? Do you believe they 
are highly addictive? If so, does that affect your willingness to prescribe them? 
4) Are you familiar with the recent regulations imposed upon the states prescription 
monitoring program?   
5) If yes, can you describe how the regulations have affected you doing your job? 
6) In your professional opinion, do you believe that prescription monitoring programs 
are successful in reducing abuse and misuse of prescription drugs? 
7) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in 
MA? If yes to either, can you elaborate on how so? 
8) In your opinion, do you believe that regulating the states prescription drug monitoring 
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Appendix F  
 
1) How long have you been working as a substance abuse counselor? 
2) Do you treat patients who are abusing and/or misusing drugs containing opioids? 
3) How effective do you think opioids are in terms of treating pain? Do you believe they are 
highly addictive?  
4) Where do majority of the patients you see obtain the opioids they abuse and/or misuse?   
5) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in 
MA? If yes to either, can you elaborate on how so? 
6) Are you familiar with the recent regulations imposed upon the states prescription 
monitoring program?   
7) Do you believe that prescription monitoring programs are successful in reducing abuse 
and misuse of prescription drugs? 
8) In your opinion, do you believe that regulating states prescription monitoring programs 
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Appendix G  
 
1) How long has it been since you stopped using prescription drugs? 
___0-12 months  
___Between 1 and 4 years  
___Between 4 years and 5 years  
___More than 5 years  
2) How did you become addicted to narcotics? (short answer below) 
 
 
3) Are you familiar with the regulations imposed upon the prescription drug industry?  
___yes ___no ___not sure    
4) When you were using where did you most often get the narcotics? 
___a friend 
___prescription from my doctor 
___prescription drug dealer 
___other   
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5) Have you ever relapsed? 
___yes ___no  
6) If yes, why triggered the relapse? (short answer below) 
 
 
 7) In your experience, where do you feel most addicts get their narcotics? (short answer below)  
 
 
 8) Do you believe that regulating the prescription drug industry (ie. instituting stricter laws for 
prescription monitoring programs, and harsher penalties for doctors that over-prescribe) has 















Dear Prospective Participant, 
 
My name is Meredith Rodman and I am a graduate student at the University of 
Massachusetts Boston in the Department of Public Policy and Public Affairs. I am conducting a 
research project examining the regulations imposed upon the prescription drug industry within 
Massachusetts as they relate to prescription monitoring programs. As a scholar in this field, I am 
hoping to interview you in person or over the phone, for about 30 to 60 minutes.  
After I complete all of my interviews, I plan to write up the results of my study.  Any 
information I use from the interviews would be presented in such a way as to ensure 
confidentiality. You could end the interview or not answer questions at any point for any reason. 
While I cannot promise any direct benefit from your participation in this study, I hope that it will 
provide systematically collected data on what scholars in the field of prescription drug 
regulations see as emerging issues. I would be pleased to provide you with a copy of what I 
write. 
University research procedures govern this project and I would be pleased to answer 
questions about these procedures at any time.  This project has been reviewed by the Institutional 
Review Board at the University of Massachusetts Boston.  Approval of this project only signifies 
that the procedures adequately protect the rights and welfare of participants.  Should you have 
any questions or concerns for the Institutional Review Board (IRB), you may contact IRB 
directly at the Office of Research Compliance at (617) 287-5374 or at human.subjects@umb.edu.  
I hope to speak with you about emerging issues in the field of prescription drug regulations. If 






Meredith Rodman          
Graduate Student          
Department of Public Policy &Public Affairs     
University of Massachusetts Boston        
Meredith.rodman@gmail.com      (508) 801-2134       
 
 
